X-Chem, Taiho establish multi-target drug discovery collaboration
This collaboration will grant Taiho access to X-Chem’s DEX technology which is based on DNA-encoded libraries of small molecules with more than 120 billion molecules. The aim of
China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.
The study will investigate the effects of once-daily closed triple combination therapy fluticasone furoate/ umeclidinium/vilanterol compared to therapy with the once-daily dual combination therapy, Relvar/Breo(R) (FF/VI). Comprising three
COMPASS is a randomized, double-blind, placebo-controlled, 26-week Phase 3 study evaluating volanesorsen in 113 patients with severe hypertriglyceridemia. The average incoming triglyceride level of patients in the study
The companies signed an exclusive option, collaboration and license agreement for the worldwide development and commercialization of Conatus’ emricasan, an investigational oral, pan-caspase inhibitor intended to treat non-alcoholic
Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders. Evotec has built an industrialised iPSC infrastructure that represents